Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
sub-chronic toxicity: oral
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: GLP guideline study (supervised by NTP)

Data source

Referenceopen allclose all

Reference Type:
publication
Title:
Unnamed
Year:
2010
Report date:
2010
Reference Type:
publication
Title:
Toxicity and carcinogenicity of androstendione in F344/N rats and B6C3F1 mice
Author:
Blystone CR et.al.
Year:
2011
Bibliographic source:
Food and Chemical Toxicology 49, 2116-2124

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
other: NTP laboratory health and safety guidelines
Qualifier:
according to guideline
Guideline:
OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
Principles of method if other than guideline:
Cited from report: "The NTP conducts its studies in compliance with its laboratory health and safety guidelines and FDA Good Laboratory Practice Regulations and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use are in accordance with the Public Health Service Policy on Humane Care and Use of Animals. Studies are subjected to retrospective quality assurance audits before being presented for public review."
GLP compliance:
yes (incl. QA statement)
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Androst-4-ene-3,17-dione
EC Number:
200-554-5
EC Name:
Androst-4-ene-3,17-dione
Cas Number:
63-05-8
Molecular formula:
C19H26O2
IUPAC Name:
androst-4-ene-3,17-dione
Details on test material:
- Name of test material (as cited in study report): Androstendione
- Lot/batch No.: H408
- Purity: > 98 %
- Stability under test conditions: The stability of the substance in the formulation was analytically verified for at least 35 days (sealed amber glass bottles; 5 °C).

Test animals

Species:
rat
Strain:
Fischer 344
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Strain: F344/N
- Source: Taconic Farms, Inc. (Germantown, NY, USA)
- Age at study initiation: 5 to 6 weeks old
- Weight at study initiation (mean): males 101 g, females 91 g
- Housing: in groups of five per cage (solid bottom polycarbonate cages)
- Diet and Water: ad libitum
- Acclimation period: 12 to 15 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): approx. 22 +/- 1.6 (72 +/- 3 °F)
- Humidity (%): 50 +/- 15
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
CMC (carboxymethyl cellulose)
Details on oral exposure:
Administration volume: 5 mL/kg

VEHICLE: 0.5 % aqueous methylcellulose
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
Dose formulations were analysed three times during the 3-month study; animal room samples were also analysed. The analytical method used was HPLC.
Duration of treatment / exposure:
14 weeks
Frequency of treatment:
once daily, 5 days/week
Doses / concentrations
Remarks:
Doses / Concentrations:
1, 5, 10, 20, and 50 mg/kg bw
Basis:
actual ingested
No. of animals per sex per dose:
10; additionally 10 animals per sex and dose were treated for clinical pathology studies.
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: For dose selection results from a previously conducted 2-week study were used. In this study groups of five male and five female rats were administered 0, 1, 5, 10, 20, or 50 mg androstenedione/kg body weight in a 0.5 % aqueous methylcellulose solution by gavage, 5 days per week for 12 days. All rats survived to the end of the study, and the mean body weights of dosed groups were similar to those of the vehicle control groups. The development of cytoplasmic vacuoles within centrilobular hepatocytes in male rats was the only treatment-related effect observed.

- Rationale for selecting satellite groups: Additional 10 animals per sex and dose were treated for 23 days for clinical pathology studies.

Examinations

Observations and examinations performed and frequency:
CAGE SIDE OBSERVATIONS: Yes, all animals
- Time schedule: observed twice daily; clinical findings were recorded weekly for core study animals.

BODY WEIGHT: Yes, all animals
- Time schedule for examinations: Animals were weighed initially, on day 2 (female mice), day 3 (males), day 4 (female rats), weekly, and at the end of the studies.

CLINICAL PATHOLOGY:
Blood was collected from the retroorbital sinus of clinical pathology study rats on days 4 and 24 and from core study rats at the end of the studies for hematology and clinical chemistry.
- Hematology: automated and manual hematocrit; hemoglobin concentration; erythrocyte, nucleated erythrocytes, reticulocyte, and platelet counts; mean cell
volume; mean cell hemoglobin; mean cell hemoglobin concentration; leukocyte count and differentials
- Clinical chemistry: urea nitrogen, creatinine, total protein, albumin, alanine aminotransferase, alkaline phosphatase, creatine kinase, sorbitol dehydrogenase, and total bile acids
Sacrifice and pathology:
GROSS PATHOLOGY: Yes, necropsies were performed on core study animals
Organs weighed were heart, right kidney, liver, lung, right testis, thymus, and uterus.

HISTOPATHOLOGY: Yes, complete histopathology was performed on vehicle control and 50 mg/kg core study rats
In addition to gross lesions and tissue masses, the following tissues were examined: adrenal gland, bone, brain, clitoral gland, esophagus, eye, harderian gland, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, seminal vesicle, skin, spleen, stomach (forestomach and glandular), testis with epididymis, thymus, thyroid gland, trachea, urinary bladder, and uterus. In addition, the adrenal gland, heart, liver, mammary gland, ovary, prostate gland, and thyroid gland of rats were examined in the remaining dosed groups.

SPERM MOTILITY AND VAGINAL CYTOLOGY: At the end of the studies, sperm samples were collected from male animals in the 0, 10, 20, and 50 mg/kg groups for sperm motility evaluations. The following parameters were evaluated: spermatid heads per testis and per gram testis, spermatid counts, and epididymal spermatozoal motility and concentration. The left cauda, left epididymis, and left testis were weighed. Vaginal samples were collected for up to 12 consecutive days prior to the end of the studies from females administered 0, 10, 20, or 50 mg/kg for vaginal cytology evaluations. The percentage of time spent in the various estrous cycle stages and estrous cycle length were evaluated.
Statistics:
Survival Analysis: The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958). Statistical analyses for possible dose-related effects on survival used Cox¿s (1972) method for testing two groups for equality and Tarone¿s (1975) life table test to identify dose-related trends. All reported P values for the survival analyses are two sided.
Calculation of Incidences were performed: Incidences of neoplasms or nonneoplastic lesions as the numbers of animals bearing such lesions at a specific anatomic site and the numbers of animals with that site examined microscopically.
Analysis of Neoplasm and Nonneoplastic Lesion Incidences: Poly-k test (Bailer and Portier, 1988; Portier and Bailer, 1989; Piegorsch and Bailer, 1997) to assess neoplasm and nonneoplastic lesion prevalence. Tests of significance included pairwise comparisons of each dosed group with controls and a test for an overall dose-related trend. Continuity-corrected Poly-3 tests were used in the analysis of lesion incidence, and reported P values are one sided.
Analysis of Continuous Variables: Two approaches were employed to assess the significance of pairwise comparisons between dosed and control groups in the analysis of continuous variables. 1) Parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972). 2) Nonparametric multiple comparison methods of Shirley (1977) (as modified by Williams, 1986) and Dunn (1964).

Results and discussion

Results of examinations

Details on results:
CLINICAL SIGNS AND MORTALITY
All rats survived to the end of the study.

BODY WEIGHT AND WEIGHT GAIN
The mean body weights of the 20 mg/kg female group was significantly greater than those of the vehicle control group and there was significant increased weight gain in the 1, 20, and 50 mg/kg female groups.

CLINICAL PATHOLOGY
There were no changes in hematology or clinical chemistry variables that were considered attributable to androstenedione administration.

ORGAN WEIGHTS
Female thymus weights were significantly increased in the 20 and 50 mg/kg groups, which may be related to the increase in mean body weight.

GROSS PATHOLOGY
No lesions were observed through gross observation that could be attributed to the administration of androstenedione.

SPERM MOTILITY AND VAGINAL CYTOLOGY
The numbers of sperm per mg cauda epididymis in the 10, 20, and 50 mg/kg male groups and the total number of sperm per cauda epididymis in 50 mg/kg males were significantly less than those of the vehicle controls.

HISTOPATHOLOGY
No treatment-related histological lesions were observed in males or females.

Effect levels

Key result
Dose descriptor:
NOAEL
Effect level:
5 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male
Basis for effect level:
other: Steroid hormone-related effect on male fertility in the next higher dose group based on sperm investigations (The numbers of sperm per mg cauda epididymis were significantly decreased).

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

Executive summary:

Cited from NTP report:

"Groups of 10 male and 10 female core study rats were administered 0, 1, 5, 10, 20, or 50 mg androstenedione/kg body weight in a 0.5 % aqueous methylcellulose solution by gavage, 5 days per week for 14 weeks; additional groups of 10 male and 10 female clinical pathology study rats received the same doses for 23 days. All rats survived to the end of the study. The mean body weights of the 20 mg/kg female group was significantly greater than those of the vehicle control group and there was significant increased weight gain in the 1, 20, and 50 mg/kg female groups. Female thymus weights were significantly increased in the 20 and 50 mg/kg groups, which may be related to the increase in mean body weight. The numbers of sperm per mg cauda epididymis in the 10, 20, and 50 mg/kg male groups and the total number of sperm per cauda epididymis in 50 mg/kg males were significantly less than those of the vehicle controls. No treatment-related histological lesions were observed in males or females."

No NOAEL was concluded in the report, as the study served only for the purpose of dose selection for a 2 -year carcinogenicity study. As effects on male fertility revealed the most sensitive health effect in the study a NOAEL of 5 mg/kg is concluded as point of departure for the delineation of a DNEL.